Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.51 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5909057 | 0.89 | CA12 (0.58) | PLK1LMNAHPGDMAPTMEN1 | |
| SCHEMBL10789232 | 0.86 | EPHX2 (0.60) | PLK1LMNAHPGDMAPTMEN1 | |
| SCHEMBL10951282 | 0.86 | PLK1 (0.72) | PLK1LMNAHPGDMAPTMEN1 | |
| SCHEMBL1980812 | 0.84 | MEN1 (0.53) | PLK1LMNAHPGDMAPTMEN1 | |
| SCHEMBL6360077 | 0.84 | PLK1 (0.63) | PLK1LMNAKMT2AALDH1A1TDP1 | |
| SCHEMBL6078477 | 0.84 | MEN1 (0.56) | PLK1LMNAHPGDMAPTMEN1 | |
| SCHEMBL13461011 | 0.84 | HDAC3 (0.63) | PLK1LMNAHPGDMAPTMEN1 | |
| SCHEMBL13761394 | 0.84 | LMNA (0.53) | PLK1LMNAHPGDMAPTMEN1 | |
| SCHEMBL13554186 | 0.82 | HDAC6 (0.54) | PLK1LMNAHPGDMAPTMEN1 | |
| SCHEMBL8404665 | 0.82 | PLK1 (0.61) | PLK1LMNAHPGDALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022073424-A1 | SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF | 嘉兴特科罗生物科技有限公司 | 2022-04-14 | — | — | WO | disclosed |
| WO-2021022076-A1 | MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2021-02-04 | — | — | WO | disclosed |
| EP-3022184-B1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016138527-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160194316-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2016-07-07 | — | — | US | disclosed |
| US-20160031907-A1 | Substituted Benzene Compounds | Epizyme, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-8969571-B2 | Biphenyl derivatives | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140234364-A1 | TOTAL SYNTHESIS AND IMMUNOLOGICAL EVALUATION OF SACCHARIDE MOIETIES OF THE LIPOPOLYSACCHARIDE FROM NEISSERIA MENINGITIDIS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-08-21 | — | — | US | disclosed |
| US-20140234364-A1 | TOTAL SYNTHESIS AND IMMUNOLOGICAL EVALUATION OF SACCHARIDE MOIETIES OF THE LIPOPOLYSACCHARIDE FROM NEISSERIA MENINGITIDIS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-08-21 | — | — | US | disclosed |
| US-20140235864-A1 | BIPHENYL DERIVATIVES | THERAVANCE, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-4160095-A | PROSTAGLANDINS; ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1979-07-03 | — | — | US | disclosed |
| US-4157441-A | PROSTAGLANDINS, ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1979-06-05 | — | — | US | disclosed |
| US-4151351-A | PROSTAGLANDINS, ANTIINFLAMMATORY | THE UPJOHN COMPANY (US) | 1979-04-24 | — | — | US | disclosed |
| US-4131738-A | 6-Hydroxy-PGE1 compounds | THE UPJOHN COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4128713-A | 6,7-Didehydro-PGI1 compounds | THE UPJOHN COMPANY (US) | 1978-12-05 | — | — | US | disclosed |
| US-4126744-A | PROSTACYCLIN, MUSCLE STIMULANTS, PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-4112224-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4109082-A | PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS | THE UPJOHN COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031907-A1 | Substituted Benzene Compounds | CYP1B1, CYP4B1, CYP2B6 | PLK1 1268/4885LMNA 1797/4885HPGD 98/4885 |
| US-20140235864-A1 | BIPHENYL DERIVATIVES | ADRB1, ADRB2, ADRB3 | PLK1 2967/4885LMNA 3024/4885HPGD 3026/4885 |
| US-20160194316-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | PLK1 998/4885LMNA 1888/4885HPGD 133/4885 |
| US-20140234364-A1 | TOTAL SYNTHESIS AND IMMUNOLOGICAL EVALUATION OF SACCHARIDE MOIETIES OF THE LIPOPOLYSACCHARIDE FROM NEISSERIA MENINGITIDIS | FUT5, DAD1, STT3B | PLK1 2881/4885LMNA 1379/4885HPGD 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.